Antifibrotic effects of bezafibrate and pioglitazone against thioacetamide-induced liver fibrosis in albino rats
Activation of hepatic stellate cells is a central event in hepatic fibrogenesis that offers multiple potential sites for therapeutic interventions. Peroxisome proliferator-activated receptors are implicated in liver fibrosis. We aimed to evaluate the effect of bezafibrate and pioglitazone on a thioacetamide (TAA) rat model of liver fibrosis and to clarify the possible underlying mechanisms. Rats received intraperitoneal injections of TAA for 6 weeks. Daily oral treatments with bezafibrate or pioglitazone were started with the first day of TAA intoxication. Serum liver function tests, hepatic malondialdehyde (MDA), total nitrite and nitrate (NOx), superoxide dismutase, and hepatic histopathology were assessed to evaluate hepatic damage. Alpha smooth muscle actin (α-SMA) and tissue inhibitor metalloproteinase-1 (TIMP-1) and caspase-3 were also assessed. The TAA group experienced significant deterioration of liver functions, increased oxidative stress, and increased liver tissue NOx. Administration of bezafibrate or pioglitazone resulted in significant improvement of all liver functions and reduced oxidative stress in hepatic tissues. Only administration of bezafibrate significantly reduced NOx levels. Liver tissues from the TAA-treated group showed disrupted normal architecture. Administration of bezafibrate or pioglitazone attenuated this picture. Stronger α-SMA expression was detected in the TAA group. Treatment with bezafibrate or pioglitazone decreased the α-SMA expression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
Canadian journal of physiology and pharmacology - 99(2021), 3 vom: 01. März, Seite 313-320 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ibrahim, Salwa A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.03.2021 Date Revised 22.03.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1139/cjpp-2020-0159 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312969732 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312969732 | ||
| 003 | DE-627 | ||
| 005 | 20231225145549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1139/cjpp-2020-0159 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM312969732 | ||
| 035 | |a (NLM)32721217 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ibrahim, Salwa A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antifibrotic effects of bezafibrate and pioglitazone against thioacetamide-induced liver fibrosis in albino rats |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2021 | ||
| 500 | |a Date Revised 22.03.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Activation of hepatic stellate cells is a central event in hepatic fibrogenesis that offers multiple potential sites for therapeutic interventions. Peroxisome proliferator-activated receptors are implicated in liver fibrosis. We aimed to evaluate the effect of bezafibrate and pioglitazone on a thioacetamide (TAA) rat model of liver fibrosis and to clarify the possible underlying mechanisms. Rats received intraperitoneal injections of TAA for 6 weeks. Daily oral treatments with bezafibrate or pioglitazone were started with the first day of TAA intoxication. Serum liver function tests, hepatic malondialdehyde (MDA), total nitrite and nitrate (NOx), superoxide dismutase, and hepatic histopathology were assessed to evaluate hepatic damage. Alpha smooth muscle actin (α-SMA) and tissue inhibitor metalloproteinase-1 (TIMP-1) and caspase-3 were also assessed. The TAA group experienced significant deterioration of liver functions, increased oxidative stress, and increased liver tissue NOx. Administration of bezafibrate or pioglitazone resulted in significant improvement of all liver functions and reduced oxidative stress in hepatic tissues. Only administration of bezafibrate significantly reduced NOx levels. Liver tissues from the TAA-treated group showed disrupted normal architecture. Administration of bezafibrate or pioglitazone attenuated this picture. Stronger α-SMA expression was detected in the TAA group. Treatment with bezafibrate or pioglitazone decreased the α-SMA expression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PPAR | |
| 650 | 4 | |a antifibrosant | |
| 650 | 4 | |a antifibrotic | |
| 650 | 4 | |a antioxidants | |
| 650 | 4 | |a antioxydants | |
| 650 | 4 | |a bezafibrate | |
| 650 | 4 | |a bézafibrate | |
| 650 | 4 | |a fibrose hépatique | |
| 650 | 4 | |a liver fibrosis | |
| 650 | 4 | |a pioglitazone | |
| 650 | 4 | |a récepteurs activés par les proliférateurs des peroxysomes (PPAR) | |
| 650 | 4 | |a thioacetamide | |
| 650 | 4 | |a thioacétamide | |
| 650 | 7 | |a Actins |2 NLM | |
| 650 | 7 | |a Nitrites |2 NLM | |
| 650 | 7 | |a smooth muscle actin, rat |2 NLM | |
| 650 | 7 | |a Thioacetamide |2 NLM | |
| 650 | 7 | |a 075T165X8M |2 NLM | |
| 650 | 7 | |a Malondialdehyde |2 NLM | |
| 650 | 7 | |a 4Y8F71G49Q |2 NLM | |
| 650 | 7 | |a Pioglitazone |2 NLM | |
| 650 | 7 | |a X4OV71U42S |2 NLM | |
| 650 | 7 | |a Bezafibrate |2 NLM | |
| 650 | 7 | |a Y9449Q51XH |2 NLM | |
| 700 | 1 | |a Mohamed, Mervat Z |e verfasserin |4 aut | |
| 700 | 1 | |a El-Tahawy, Nashwa F |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelrahman, Aly M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Canadian journal of physiology and pharmacology |d 1964 |g 99(2021), 3 vom: 01. März, Seite 313-320 |w (DE-627)NLM000001635 |x 1205-7541 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2021 |g number:3 |g day:01 |g month:03 |g pages:313-320 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1139/cjpp-2020-0159 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 99 |j 2021 |e 3 |b 01 |c 03 |h 313-320 | ||